Article

Merit of the paper "PP2A inhibition sensitize cancer stem cells to ABL tyrosine kinase inhibition in BCR-ABL human leukemia" authored by Lai et al. [Science Translational Medicine (2019) Vol. 11, Issue 501, eaau0416, DOI: 10.1126/scitranslmed.aau0416]

2020-02-06

Abstract excerpt

The paper by Lai et al. [1] showed that inhibition of PP-2A with LB100 or LB102 in conjunction with Tyrosine kinase Inhibitors (TKIs) was effective at targeting BCR-ABL + blast cells and insensitive leukemic stem cells (LSCs). Perotti et al. [2] has severely criticised the paper by Lai et al [2]. However, Perotti et al. [2] has failed to appreciate an important principle of the role of PP-2A as a tumor suppressor...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 5c41bb65-780c-58a7-a316-0506bb25612b
DOI: 10.14293/s2199-1006.1.sor-.ppyefvr.v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Merit of the paper "PP2A inhibition sensitize cancer stem cells to ABL tyrosine kinase inhibition in BCR-ABL human leukemia" authored by Lai et al. [Science Translational Medicine (2019) Vol. 11, Issue 501, eaau0416, DOI: 10.1126/scitranslmed.aau0416]DOI 10.14293/s2199-1006.1.sor-.ppyefvr.v1Read

PP2A inhibition sensitizes cancer stem cells to ABL tyrosine kinase inhibitors in BCR-ABL + human leukemiaSemantic proximity Read

All roads lead to PP2A: exploiting the therapeutic potential of this phosphatase.Semantic proximity Read

The protein phosphatase-2A subunit PR130 is linked to cytotoxic protein aggregate formation in mesenchymal pancreatic ductal adenocarcinoma cellsSemantic proximity Read

Protein phosphatase 1 in tumorigenesis: is it worth a closer look?Semantic proximity Read

A PP2A molecular glue overcomes RAS/MAPK inhibitor resistance in KRAS-mutant non-small cell lung cancer.Semantic proximity Read

CIP2A Inhibits PP2A in Human MalignanciesSemantic proximity Read

PP2A is a therapeutically targetable driver of cell fate decisions via a c-Myc/p21 axis in human and murine acute myeloid leukemiaSemantic proximity Read

Cancerous inhibitor of PP2A (CIP2A) at diagnosis of chronic myeloid leukemia is a critical determinant of disease progressionSemantic proximity Read

Functional importance of PP2A regulatory subunit loss in breast cancer.Semantic proximity Read

Reactivating PP2A by FTY720 as a novel therapy for AML with C-KIT tyrosine kinase domain mutation.Semantic proximity Read

The PP2A subunit PR130 is a key regulator of cell development and oncogenic transformationSemantic proximity Read

SET-PP2A complex as a new therapeutic target in KMT2A (MLL) rearranged AML.Semantic proximity Read